We are pleased to announce that Clinigen Group plc (‘Clinigen’, AIM: CLIN), a global pharmaceutical and services company, has acquired CSM from Great Point Partners (“GPP”), the Greenwich-based private investment firm focused exclusively on the health care industry.
Shaun Chilton, CEO of Clinigen, said: “This acquisition is an exciting next step in line with our strategy and realising our vision to become the global trusted leader in access to medicines.”
Rohan Saikia, Managing Director at GPP commented: “We are very proud of what we accomplished with CEO Scott Houlton and the entire CSM team in our two years of ownership.”
“Great Point’s expertise in pharmaceutical services and support were critical components of our success, enabling us to build a high growth global company in a short period of time,” Scott Houlton, Chief Executive Officer at CSM, stated. “This has been a highly rewarding partnership for the CSM team.”
“With Scott’s leadership we transformed CSM from a company with operations at two U.S. sites only into a global company with operations also in Belgium and Germany that resulted in a dramatic acceleration of growth,” added Stephen Weaver, Senior Vice President at GPP.
At CSM we are confident that our specialist capabilities combined with Clinigen’s supply & distribution network provide an opportunity to offer our customers the choice of a combined end-to-end offer which is increasingly requested. With CSM, Clinigen will be able to offer a significantly improved capability to support the full life-cycle of a medicine, from clinical trials to unlicensed to licensed, across an increasing number of territories.
Read the full press releases here:
How can our combined capabilities help your project? Get in touch and schedule your 20-minute, no-cost consultation with a clinical supplies services expert.